UBS has completed the sale of a £555m (€819m) worth of shares in AstraZeneca, the UK drugs company, for Investor, the Swedish investment company.The block was equal to 1.25% of AstraZeneca's share capital.

The bank placed 21.2 million AstraZeneca shares at £26.17 each, a 1.4% discount to the closing price of £26.54 in London on Tuesday. AstraZeneca shares were trading higher than the sale price at £26.21 at 10:01 GMT.